ELVN

Enliven Therapeutics, Inc. NASDAQ Listed Mar 12, 2020

Healthcare ·Biotechnology ·US · enliventherapeutics.com

$40.27

Pre-mkt $40.51 +0.55%

Mkt Cap $2.5B

52w Low $14.79 75.5% of range 52w High $48.53

50d MA $37.14 200d MA $25.17

P/E (TTM) -22.8x

EV/EBITDA -6.5x

P/B 5.1x

Debt/Equity 0.0x

ROE -22.6%

P/FCF -12.4x

RSI (14) —

ATR (14) —

Beta 0.49

50d MA $37.14

200d MA $25.17

Avg Volume 1.1M

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

SIC Code

2834

CIK (SEC)

1672619

Phone

720 647 8519

6200 Lookout Road · Boulder, CO 80301 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	-0.42	-0.48	-14.3%	28.75	-0.6%	+4.3%	+1.9%	+2.4%	+3.4%	+5.2%	—
Nov 12, 2025	AMC	-0.43	-0.32	+25.6%	20.30	+0.0%	-0.1%	+8.7%	+7.2%	+11.3%	+8.9%	—
Aug 13, 2025	AMC	-0.53	-0.49	+7.5%	19.99	-0.3%	-1.1%	+1.2%	-1.2%	-1.2%	-1.7%	—
May 14, 2025	AMC	-0.51	-0.57	-11.8%	19.89	-2.3%	-10.4%	-15.2%	-15.3%	-12.6%	-14.9%	—
Mar 13, 2025	AMC	-0.53	-0.46	+13.2%	20.29	+4.0%	+2.2%	+3.7%	-0.0%	+3.0%	+3.1%	—
Nov 13, 2024	AMC	-0.52	-0.48	+7.7%	25.80	+2.2%	-3.4%	-5.4%	-3.5%	+1.5%	-1.4%	—
Aug 13, 2024	AMC	-0.58	-0.41	+29.3%	21.52	+4.3%	+1.3%	+10.5%	+10.2%	+9.3%	+3.6%	—
May 14, 2024	AMC	-0.58	-0.54	+6.9%	23.87	+4.1%	+0.5%	-0.3%	-3.5%	+0.5%	-4.1%	—
Mar 14, 2024	AMC	-0.56	-0.47	+16.1%	11.54	-3.6%	+3.7%	+9.5%	+52.0%	+66.5%	+56.5%	—
Nov 9, 2023	AMC	-0.49	-0.51	-4.1%	11.55	+0.1%	-1.5%	-5.6%	-4.8%	-5.2%	-9.8%	—
Aug 10, 2023	AMC	-0.40	-0.41	-2.5%	17.52	-1.4%	+0.1%	-6.1%	-6.0%	-12.4%	-7.2%	—
May 11, 2023	AMC	-0.67	-0.80	-19.4%	19.10	-0.5%	+1.6%	+3.8%	+3.8%	+4.7%	+5.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.53	$35.66	+0.4%	+10.6%	+9.3%	+3.0%	+10.3%	+6.4%
Mar 25	Mizuho	Maintains	Outperform → Outperform	—	$31.15	$33.76	+8.4%	+14.1%	+26.1%	+24.7%	+17.5%	+25.8%
Jul 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.65	$20.04	+2.0%	+5.0%	+5.5%	-0.3%	+1.4%	+9.8%
Jun 16	Baird	Maintains	Outperform → Outperform	—	$21.91	$23.38	+6.7%	+5.4%	-0.5%	-1.6%	-2.8%	-7.4%
May 16	Jones Trading	Maintains	Buy → Buy	—	$17.82	$17.73	-0.5%	-5.4%	-5.4%	-2.5%	-5.0%	-5.9%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.89	$19.44	-2.3%	-10.4%	-15.2%	-15.3%	-12.6%	-14.9%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.92	$20.64	-1.3%	+0.8%	+7.4%	+1.9%	-1.6%	+2.8%
Nov 15	Baird	Maintains	Outperform → Outperform	—	$24.92	$25.00	+0.3%	-2.0%	-0.1%	+5.1%	+2.0%	+2.0%
Oct 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.54	$25.70	+0.6%	+1.8%	-0.9%	-0.1%	+7.8%	+7.5%
Mar 29	Jefferies	Maintains	Buy → Buy	—	$23.49	$23.75	+1.1%	+2.0%	-5.7%	-6.8%	-5.7%	-3.2%
Mar 3	TD Cowen	Maintains	Outperform → Outperform	—	$23.45	$24.80	+5.8%	-5.8%	-6.7%	-9.6%	-4.3%	-9.6%

Data updated apr 25, 2026 7:00am · Source: massive.com